布洛芬、萘普生与塞来昔布对关节炎患者血压的差异影响:PRECISION-ABPM 试验
PRECISION-ABPM 是 PRECISION 的子研究,在 60 个中心纳入 444 例有关节炎且存在冠状动脉疾病证据或高风险的患者,随机接受塞来昔布、布洛芬或萘普生治疗 4 个月,评估 24 小时动态血压。结果显示布洛芬较塞来昔布显著升高收缩压并增加新发高血压发生率。
要点
- 布洛芬较塞来昔布显著升高 24 小时平均收缩压(差值 -3.9 mmHg,P=0.0009)。
- 基线血压正常者中新发高血压比例:布洛芬 23.2%、萘普生 19.0%、塞来昔布 10.3%。
- 塞来昔布与萘普生、萘普生与布洛芬的血压差异未达统计学显著。
核心结论
- 在关节炎患者中,与选择性 COX-2 抑制剂塞来昔布相比,非选择性 NSAID 布洛芬与 24 小时收缩压显著升高及新发高血压发生率更高相关。
研究设计与样本
- PRECISION-ABPM 为双盲、随机、多中心非劣效心血管安全性试验,在 60 个中心纳入 444 例骨关节炎(92%)或类风湿关节炎(8%)且存在冠状动脉疾病证据或高风险的患者。
- 患者按 1:1:1 分配接受塞来昔布(100-200 mg bid)、布洛芬(600-800 mg tid)或萘普生(375-500 mg bid)及匹配安慰剂,评估 4 个月后 24 小时动态血压变化。
主要发现
- 塞来昔布、布洛芬和萘普生组 24 小时平均收缩压变化分别为 -0.3 mmHg(95%CI -2.25, 1.74)、3.7 mmHg(95%CI 1.72, 5.58)和 1.6 mmHg(95%CI -0.40, 3.57)。
- 塞来昔布与布洛芬间收缩压差异为 -3.9 mmHg(P=0.0009),塞来昔布与萘普生间为 -1.8 mmHg(P=0.12),萘普生与布洛芬间为 -2.1 mmHg(P=0.08)。
- 基线血压正常者中新发高血压(24 小时平均收缩压≥130 和/或舒张压≥80 mmHg)比例:布洛芬 23.2%、萘普生 19.0%、塞来昔布 10.3%;塞来昔布 vs 布洛芬 OR 0.39(P=0.004),vs 萘普生 OR 0.49(P=0.03)。
临床怎么用
- 对存在冠状动脉疾病证据或高风险的关节炎患者,选择 NSAID 时应考虑其对血压的影响,布洛芬可能较塞来昔布更易升高血压并诱发新发高血压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Non-steroidal anti-inflammatory drugs (NSAIDs), both non-selective and selective cyclooxygenase-2 (COX-2) inhibitors, are among the most widely prescribed drugs worldwide, but associate with increased blood pressure (BP) and adverse cardiovascular (CV) events. PRECISION-ABPM, a substudy of PRECISION was conducted at 60 sites, to determine BP effects of the selective COX-2 inhibitor celecoxib vs. the non-selective NSAIDs naproxen and ibuprofen. METHODS AND RESULTS: In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 ± 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100-200 mg bid), ibuprofen (600-800 mg tid), or naproxen (375-500 mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4 months. The change in mean 24-h systolic BP (SBP) in celecoxib, ibuprofen and naproxen-treated patients was -0.3 mmHg [95% confidence interval (CI), -2.25, 1.74], 3.7 (95% CI, 1.72, 5.58) and 1.6 mmHg (95% CI, -0.40, 3.57), respectively. These changes resulted in a difference of - 3.9 mmHg (P = 0.0009) between celecoxib and ibuprofen, of - 1.8 mmHg (P = 0.12) between celecoxib and naproxen, and of - 2.1 mmHg (P = 0.08) between naproxen and ibuprofen. The percentage of patients with normal baseline BP who developed hypertension (mean 24-h SBP ≥ 130 and/or diastolic BP ≥ 80 mmHg) was 23.2% for ibuprofen, 19.0% for naproxen, and 10.3% for celecoxib (odds ratio 0.39, P = 0.004 and odds ratio 0.49, P = 0.03 vs. ibuprofen and naproxen, respectively). CONCLUSIONS: In PRECISION-ABPM, allocation to the non-selective NSAID ibuprofen, compared with the COX-2 selective inhibitor celecoxib was associated with a significant increase of SBP, and a higher incidence of new-onset hypertension. CLINICALTRIALS: gov number NCT00346216.
引用
- Ruschitzka F, Borer JS, Krum H, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017. PMID: 29020251. doi:10.1093/eurheartj/ehx508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。